|
|
706F Forest Street
Charlottesville, VA 22903 USA
phone:
434-984-9723
fax:
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
www.contravac.com |
|
| |
 |
| Summary Description |
| ContraVac develops innovative diagnostics products for men who seek actionable information about their fertility health but wish to test themselves at home. |
 |
| Management |
|
|
|
|
|
|
|
|
|
Description |
| ContraVac develops products for male reproductive healthcare in cooperation with the Center for Research in Contraceptive and Reproductive Health at the University of Virginia. ContraVac is dedicated to developing and commercializing research discoveries into innovative diagnostics for male reproductive health care. |
 |
| Products / Services |
ContraVacs family of SpermCheck products have been developed to meet the needs of millions of men who seek actionable information about their fertility health but wish to test themselves at home to avoid the indignities associated with traditional semen analysis.
|
 |
| Technology / Differentiation |
| ContraVacs platform technology is based on the ongoing research conducted at the Center for Contraceptive and Reproductive Health at the University of Virginia where the discovery of sperm specific biomarkers and the subsequent development of specific antibody reagents directed toward these biomarkers, will be applied to various existing commercial diagnostic formats. These biomarkers (protein antigens) possess certain characteristics and properties that lend themselves to be used as valuable tools in diagnostic assays; they all are highly sperm specific (only expressed in mature sperm) and highly expressed (abundant). As a result, these biomarkers can be used in various standardized diagnostic formats such as lateral flow immunodiagnostic devices (similar to home pregnancy tests) and Elisa assays. |
 |
 |
| Status |
| SpermCheck Vasectomy will be commercially available in the Summer of 2008 and SpermCheck Fertility at the end of 2008. |
 |
|
|
|
|